The use of corifollitropin alfa in overlapped doses, in a desogestrel-primed ovarian stimulation regimen, as a new protocol towards an extremely patient-friendly approach: a case report
Juliana Késia Araújo da Fonseca, Bárbara Veloso de Ávila Chaves, Maria Julia Ferreira de Carvalho Mariano Rodrigues da Cunha, Estella Thaísa Sontag dos Reis, Nayara Santos Soares, Bruno Ramalho de Carvalho
Abstract
Objectives: To report the well-succeeded use of a new extremely patient-friendly COS protocol, using overlapping doses of corifollitropin alfa in a once-a-day pill desogestrel-primed regimen. Methods: Case report. Results: 37 years old nuligesta, attempting social egg freezing. Conclusions: Overlapping doses of corifollitropin alfa plus desogestrel-priming stimulation protocol yields a satisfactory number of mature oocytes, presenting an interesting and innovative option towards an improvement of comfort and a reduction in emotional and financial burdens for social egg freezing cycles.
Keywords
References
1. Verberg MF, Eijkemans MJ, Heijnen EM, Broekmans FJ, Klerk C, Fauser BC, et al. Why do couples drop-out from IVF treatment? A prospective cohort study. Hum Reprod. 2008;23(9):2050-5. http://dx.doi.org/10.1093/humrep/den219. PMid:18544578.
2. Huisman D, Raymakers X, Hoomans EH. Understanding the burden of ovarian stimulation: fertility expert and patient perceptions. Reprod Biomed Online. 2009;19(Suppl 2):5-10. http://dx.doi.org/10.1016/S1472-6483(10)60271-4. PMid:19891842.
3. Troude P, Guibert J, Bouyer J, de la Rochebrochard E; DAIFI Group. Medical factors associated with early IVF discontinuation. Reprod Biomed Online. 2014;28(3):321-9. http://dx.doi.org/10.1016/j.rbmo.2013.10.018. PMid:24461478.
4. Pennings G, Ombelet W. Coming soon to your clinic: patient-friendly ART. Hum Reprod. 2007;22(8):2075-9. http://dx.doi.org/10.1093/ humrep/dem158. PMid:17584748.
5. Devroey P, Aboulghar M, Garcia-Velasco J, Griesinger G, Humaidan P, Kolibianakis E, et al. Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod. 2008;24(4):764-74. http://dx.doi.org/10.1093/humrep/den468. PMid:19153090.
6. Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod. 2002;17(8):1987-93. http://dx.doi.org/10.1093/humrep/17.8.1987. PMid:12151425.
7. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24(12):3063-72. http://dx.doi.org/10.1093/humrep/dep291. PMid:19684043.
8. Corifollitropin alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online. 2010;21(1):66-76. http://dx.doi.org/10.1016/j.rbmo.2010.03.019. PMid:20483664.
9. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70.e3. http://dx.doi.org/10.1016/j.fertnstert.2015.03.022. PMid:25956370.
10. Hossein Rashidi B, Tarafdari A, Ghazimirsaeed ST, Shahrokh Tehraninezhad E, Keikha F, Eslami B, et al. Comparison of dydrogesterone and GnRH antagonists for prevention of premature LH surge in IVF/ICSI cycles: a randomized controlled trial. J Family Reprod Health. 2020;14(1):14-20. http://dx.doi.org/10.18502/jfrh.v14i1.3783. PMid:32863834.
11. Melo AS, Paula CTV, Santos TLD, Faria VAC, Rufato MAF, Barboza RP, et al. Corifollitropin alpha, clomiphene citrate and dydrogesterone without daily gonadotrophin: a new option of a friendly protocol for high-responder oocyte donors. JBRA Assist Reprod. 2022;26(2):315-20. PMid:34672261.
12. Zhu X, Ye H, Fu Y. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine. 2016;95(28):e4193. http://dx.doi.org/10.1097/MD.0000000000004193. PMid:27428219.
13. Zhu X, Ye H, Fu Y. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a “freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertil Steril. 2017;107(2):379-86.e4. http://dx.doi.org/10.1016/j.fertnstert.2016.10.030. PMid:27865446.
14. Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine. 2015;94(21):e909. http://dx.doi.org/10.1097/ MD.0000000000000909. PMid:26020402.
15. Martínez F, Clúa E, García S, Coroleu B, Polyzos NP, Barri PN. Does LH suppression by progesterone-primed ovarian stimulation compared with GnRH antagonist affect live birth rate among oocyte recipients? Reprod Biomed Online. 2020;40(5):661-7. http://dx.doi.org/10.1016/j.rbmo.2020.01.016. PMid:32268981.
16. Martínez F, Rodriguez-Purata J, Beatriz Rodríguez D, Clua E, Rodriguez I, Coroleu B. Desogestrel versus antagonist injections for LH suppression in oocyte donation cycles: a crossover study. Gynecol Endocrinol. 2019;35(10):878-83. http://dx.doi.org/10.10 80/09513590.2019.1604661. PMid:31062995.
17. Martínez F, Rodriguez-Purata J, Clua E, Garcia S, Coroleu B, Polyzos N. Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: retrospective and comparative study. Gynecol Endocrinol. 2019;35(10):884-9. http://dx.doi.org/10.1080/09513590.2019.1604662. PMid:31081407.
18. Shibasaki S, Hattori H, Koizumi M, Nagaura S, Toya M, Igarashi H, et al. Chlormadinone acetate in progestin-primed ovarian stimulation does not negatively affect clinical results. Reprod Med Biol. 2023;22(1):e12519. http://dx.doi.org/10.1002/rmb2.12519. PMid:37265782.
19. Huang CY, Chen GY, Shieh ML, Li HY. Validating the use of corifollitropin alfa in progestin-primed ovarian stimulation protocol on normal and high responders by comparing with conventional antagonist protocol: a retrospective study. Life. 2020;10(6):90. http://dx.doi.org/10.3390/life10060090. PMid:32575849.
20. Huang TC, Huang MZ, Seow KM, Yang IJ, Pan SP, Chen MJ, et al. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol. Sci Rep. 2021;11(1):22732. http://dx.doi.org/10.1038/s41598-021-02227-w. PMid:34815477.
21. Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Muñoz M, et al. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013;26(3):253-9. http://dx.doi.org/10.1016/j. rbmo.2012.11.015. PMid:23352098.
22. Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Hum Reprod Update. 2021;27(1):48-66. http://dx.doi.org/10.1093/ humupd/dmaa040. PMid:33016316.
23. Cui L, Lin Y, Wang F, Chen C. Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis. Arch Gynecol Obstet. 2021;303(3):615-30. http://dx.doi.org/10.1007/s00404-020-05939-y. PMid:33433705.
24. Lin G, Zhong X, Li S, Liu X, Xu L. The clinical value of progestin-primed ovarian stimulation protocol for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1232935. http://dx.doi.org/10.3389/fendo.2023.1232935. PMid:37670890.
25. Wang L, Wang J, Zhang Y, Qian C, Wang X, Bai J, et al. Analysis of euploidy rates in preimplantation genetic testing for aneuploidy cycles with progestin-primed versus GnRH agonist/antagonist protocol. Eur J Med Res. 2023;28(1):28. http://dx.doi.org/10.1186/ s40001-023-01000-1. PMid:36642707.
26. la Marca A, Capuzzo M, Sacchi S, Imbrogno MG, Spinella F, Varricchio MT, et al. Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation. Hum Reprod. 2020;35(6):1325-31. http://dx.doi.org/10.1093/humrep/deaa068. PMid:32395749.
Submitted date:
10/20/2023
Accepted date:
11/02/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email